{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3 / Table 1",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Multiple references to the Schedule of Activities (SoA) for timing of study procedures, assessments, and data collection, cited in sections 3, 7.1, 7.2, 8.2.3, 8.2.4, 8.5, 8.6, and 9.4.3."
      },
      {
        "id": "ref_2",
        "name": "Study Assessments Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from the amendment summary table to Section 8 for details on procedures specific to screening sites in the US."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6 / Table 7",
        "sectionTitle": "Dose Modification",
        "description": "Multiple references to dose modification criteria for safety events, such as elevated transaminases or anemia, cited in sections 2.3.1, 4.1, and 7.1."
      },
      {
        "id": "ref_4",
        "name": "Adverse Event Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Multiple references to procedures for recording, evaluating, and following up on Adverse Events (AEs) and Serious Adverse Events (SAEs), cited throughout Section 8.3."
      },
      {
        "id": "ref_5",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Investigator's Brochure (IB)",
        "description": "Multiple references to the Investigator's Brochure (IB) for background data on risks and nonclinical data, cited in sections 2.3.1 and 4.2."
      },
      {
        "id": "ref_6",
        "name": "Contraceptive Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from lifestyle considerations (Section 5.3) to the section describing appropriate contraceptive methods."
      },
      {
        "id": "ref_7",
        "name": "Eligibility Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1 / 5.2",
        "sectionTitle": "Inclusion Criteria / Exclusion Criteria",
        "description": "Cross-references within the study population section, such as the reference from Lifestyle Considerations (5.3) to Exclusion Criteria (5.2) regarding blood donation."
      },
      {
        "id": "ref_8",
        "name": "Discontinuation Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal",
        "description": "Reference from the Electrocardiograms section (8.2.3) to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_9",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2 / Table 9",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from the Clinical Safety Laboratory Assessments section (8.2.4) to the list of required laboratory tests."
      },
      {
        "id": "ref_10",
        "name": "Balance Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Cross-references from Pharmacokinetics (8.5) and Biomarkers (8.8) sections to details of copper and molybdenum measurement in food, drink, urine, and feces."
      },
      {
        "id": "ref_11",
        "name": "Analysis Populations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3 / Table 8",
        "sectionTitle": "Populations for Analyses",
        "description": "Reference to Table 8 for the definitions of the analysis population sets."
      },
      {
        "id": "ref_12",
        "name": "Adaptive Design Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference from Overall Design (4.1) to the table describing adaptive design features."
      },
      {
        "id": "ref_13",
        "name": "Pregnancy Section Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference from discontinuation criteria (7.1) to the pregnancy section."
      },
      {
        "id": "ref_14",
        "name": "Lost to Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference from the AE/SAE follow-up section (8.3.3) to the definition of lost to follow-up."
      },
      {
        "id": "ref_15",
        "name": "Genetics Section Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from the Retained and Biobanked Sample section (8.3.6) clarifying that genetic testing will not be performed."
      },
      {
        "id": "ref_16",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from section 2.3.1.1 to the section on COVID-19 vaccine risks."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, the US Food and Drug Administration’s (FDA) regulation at 21 CFR part 312.30(b), and any applicable local regulations.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_6",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4. Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Current protocol version. Clarifies study procedures across US sites to facilitate recruitment.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol."
      }
    ],
    "summary": {
      "referenceCount": 16,
      "annotationCount": 6,
      "versionCount": 5
    }
  }
}